This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfisterer, M. E. Articles by Burkart, F. Search for Related Content PubMed PubMed Citation Articles by Pfisterer, M. E. Articles by Burkart, F.

Circulation, Vol 87, 309-311, Copyright © 1993 by American Heart Association

ARTICLES

Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction

ME Pfisterer, W Kiowski, H Brunner, D Burckhardt and F Burkart
Department of Internal Medicine, University Hospital Clinics, Basel, Switzerland.

BACKGROUND. In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction. To assess whether this beneficial effect persisted despite discontinuation of amiodarone after 1 year, the long- term outcomes of all patients of the amiodarone-treated group (initially n = 98) and those of the control group (n = 114) were assessed. METHODS AND RESULTS. After a mean follow-up of 72 (55-125) months, information on 96% of patients (203 of 212) was obtained regarding survival or cause of death. The probability of death after 84 months according to actuarial life-table analysis (Kaplan-Meier) was 30% for the amiodarone-treated patients and 45% for control patients. For the total follow-up, mortality remained significantly lower in the amiodarone group versus the control group regarding all deaths (p = 0.03) as well as cardiac death (p = 0.047). This mortality reduction was entirely due to the first-year amiodarone effect, since there was no significant mortality difference between groups when considering survival after discontinuation of amiodarone only. CONCLUSIONS. These data suggest that the beneficial effect of amiodarone on survival in this high-risk group of patients persists for several years. In addition, the results stress the importance of early treatment after myocardial infarction, whereas the rate of sudden death and all cardiac death is low (1.6% and 4.1% per year, respectively) during late follow- up and therefore may not warrant further therapy.

This article has been cited by other articles:

				F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza CHAPTER 17 Chronic Ischaemic Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, K. Fox, M. A. A. Garcia, D. Ardissino, P. Buszman, P. G. Camici, F. Crea, C. Daly, G. De Backer, P. Hjemdahl, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology Eur. Heart J., June 1, 2006; 27(11): 1341 - 1381. [Full Text] [PDF]

				M. P. Anstadt and J. E. Lowe Cardiopulmonary Resuscitation Card. Surg. Adult, January 1, 2003; 2(2003): 471 - 494. [Full Text]

				P. Della Bella, R. De Ponti, J.A.S. Uriarte, C. Tondo, C. Klersy, C. Carbucicchio, C. Storti, S. Riva, and M. Longobardi Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia. Long-term outcome in relation to acute electrophysiological findings Eur. Heart J., March 1, 2002; 23(5): 414 - 424. [Abstract] [Full Text] [PDF]

				C. A Karle, V. A.W Kreye, D. Thomas, K. Rockl, S. Kathofer, W. Zhang, and J. Kiehn Antiarrhythmic drug carvedilol inhibits HERG potassium channels Cardiovasc Res, February 1, 2001; 49(2): 361 - 370. [Abstract] [Full Text] [PDF]

				P. J. Welch, R. L. Page, and M. H. Hamdan Management of ventricular arrhythmias: A trial-based approach J. Am. Coll. Cardiol., September 1, 1999; 34(3): 621 - 630. [Abstract] [Full Text] [PDF]

				N. A. Omoigui, F. I. Marcus, J. W. Mason, E. A. Hahn, V. L. Hartz, and M. A. Hlatky Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM) Circulation, February 15, 1995; 91(4): 1070 - 1076. [Abstract] [Full Text]

				D. G. Zarembski, P. E. Nolan Jr, M. K. Slack, and A. C. Caruso Empiric Long-term Amiodarone Prophylaxis Following Myocardial Infarction: A Meta-Analysis Arch Intern Med, December 13, 1993; 153(23): 2661 - 2667. [Abstract] [PDF]

				LONG-TERM BENEFITS OF AMIODARONE AFTER ACUTE MI Journal Watch (General), March 5, 1993; 1993(305): 4 - 4. [Full Text]